Distinguish between revenue codes 637, 250 when billing self-administered drugs
APCs Insider, September 5, 2008
Want to receive articles like this one in your inbox? Subscribe to APCs Insider!
QUESTION: Is it inappropriate to bill all self-administered drug (SAD) charges as integral to a procedure using revenue code 250, or should we bill the SADs to the patient using revenue code 637? Is this the hospital's choice?
ANSWER: Consider the following guidelines when billing SADs to Medicare. (Note that SAD guidelines apply to outpatients only, so the following answer applies to outpatients and also includes Part B only claims.)
You should assign revenue code 637 to SADs to differentiate them from drugs covered under revenue code 250. You can assign a SAD to revenue code 250 and still place it in the non-covered column of the UB-04; however, since most billing rules are specific for revenue codes, this practice creates a large potential for error. Note that some FIs/MACs have stated that facilities must report SADs under revenue code 637. More importantly, you should designate a SAD separately from other drugs integral to a procedure. It is inappropriate to disregard this practice.
Typically, providers use revenue codes to assign responsibility to the patient or payer. The claim editing dictionary in your billing software determines how to assign a particular item. It may be possible to set up an item?s charge code in the dictionary to reflect either facility or patient responsibility. This means that an item could have either revenue code 250 or 637 assigned in the Charge Description Master. Then, when you assign responsibility at the charge code level in the claim dictionary, you could assign it to the patient. Each provider should evaluate their individual system?s capability.
CMS Transmittal No. A-02-129, dated January 3, 2003, states the following:
Neither the OPPS nor other Medicare payments rules regulate the provision or billing by hospitals of noncovered drugs to Medicare beneficiaries. However, a hospital's decision not to bill the beneficiary for noncovered drugs potentially implicates other statutory and regulatory provisions, including the prohibition on inducement to beneficiaries, section 1128A(a)(5) of the Act, or the anti-kickback statute, section 1128B(b) of the Act. Providers are encouraged to familiarize themselves with the specific provisions cited in these Acts in order to ensure compliance.
Want to receive articles like this one in your inbox? Subscribe to APCs Insider!
Comments
0 comments on “Distinguish between revenue codes 637, 250 when billing self-administered drugs ”
Related Products
Most Popular
- Articles
-
- Practice the six rights of medication administration
- Note similarities and differences between HCPCS, CPT® codes
- Don’t forget the three checks in medication administration
- Q/A: Correctly determining billing units for drugs
- Complications from immobility by body system
- Note from the instructor: CMS issues guidance on hospital inpatient admission order and certification requirements, Part I: Physician certification
- Differentiate between types of wound debridement
- What does case-mix index mean to you?
- Joint Commission now allows partially-used oxygen canisters in 'full' rack
- The program coordinator's role with the clinical competency committee
- E-mailed
-
- Joint Commission now allows partially-used oxygen canisters in 'full' rack
- Understand which parts of the medical record coders can use
- Teamwork makes clinical documentation management program a success at Kettering Medical Center
- Initial vs. subsequent. New vs. established. Will it be an issue?
- Five keys to creating a CHF disease management program
- Do not append modifier -52 to procedures involving equipment failure
- Dig into the details of wound care documentation
- Data gathering/reporting: One CDI specialist shares her hospital's methodology
- Communication strategies for nurse leaders
- CMS and Joint Commission clarify door-closing devices standards
- Searched